Advertisements

Proluton Depot

Quick links to important sections

Proluton Depot

Advertisements
Advertisements

Medically reviewed

Marina Burgos

Last updated on 10/01/2026

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Advertisements

Overview of Proluton Depot

Quick Facts

Property Description
Active ingredient Hydroxyprogesterone caproate (17-OHPC)
Form Oil-based solution for injection
Pharmacological class Synthetic Progestogen / Progestin
Route of administration Intramuscular (IM) injection
Origin Synthetic steroid derivative
Prescription Status Prescription Only (Rx)

Proluton Depot: Defining the Type and Classification

Proluton Depot is a prescription-only hormonal medicine containing the active pharmaceutical ingredient Hydroxyprogesterone caproate (17-OHPC), which is recognized pharmacologically as a synthetic progestogen. This compound is chemically synthesized to function as a powerful progesterone receptor agonist, placing it within the pharmacological class of progestins. Historically marketed under various trade names globally, Proluton Depot is distinguished by its specific depot formulation designed to provide a sustained hormonal effect.

Composition and Delivery: What is Hydroxyprogesterone Caproate?

The core component, Hydroxyprogesterone caproate (INN), is an ester derivative with a synthetic steroid derivative origin, possessing distinct pharmacological properties compared to the natural hormone. The medicine is exclusively supplied as a sterile oil-based solution for intramuscular (IM) injection, classifying it as a depot preparation. The addition of the caproate component to the hormone, along with the oil vehicle, creates the long-acting effect: slow and steady release from the injection site.

General Purpose: The Role of This Long-Acting Progestin

The general purpose of this medicine is to promote and maintain stability within hormone-sensitive tissues. By ensuring a continuous, long-acting supply of this synthetic progestin, Proluton Depot reinforces the necessary conditions for uterine quiescence—a state of reduced muscular excitability. This hormonal support is clinically recognized for its role in stabilizing the environment during periods when consistent progestogenic influence is critical to the integrity of the female reproductive system.

Regulatory References

  1. EMA Referral on Hydroxyprogesterone caproate
Advertisements

What side effects are possible with Proluton Depot?

Possible Side Effects and Safety Information

The safety profile for this medicine, which contains Hydroxyprogesterone caproate, is formally classified based on adverse events documented in clinical trials and post-marketing experience, reflecting the standards set by government regulatory authorities.

Frequency-Classified Adverse Reactions

The official labeling classifies the most frequent adverse reactions primarily as local effects linked to the intramuscular administration. Very common (ge 10%) side effects include injection site pain and urticaria (hives). Effects classified as common (1% to 10%) include injection site swelling, injection site pruritus (itching), nausea, and general pruritus. These classifications define the expected rate of occurrence for patients.

Adverse Event Category Example Effects (Regulatory Documented)
Local Reactions Pain, swelling, nodule, cellulitis, pruritus, erythema
Systemic Effects Nausea, diarrhea, headache, dizziness, mental depression
Skin Disorders Urticaria, rash, chloasma/melasma (skin discoloration)

Serious Adverse Reactions and Safety Constraints

The most serious documented safety concerns listed in regulatory documents involve thromboembolic events, including deep vein thrombosis, pulmonary embolism, stroke, and myocardial infarction, along with specific neuro-ocular lesions such as retinal vascular thrombosis.

Regulatory documents define strict contraindications that formally prohibit the use of this medicine in patients with a current or history of thromboembolic disorders, known or suspected hormone-sensitive cancers, undiagnosed abnormal vaginal bleeding, and severe liver disease or tumors.

Specific population safety considerations require careful monitoring for patients with existing conditions like diabetes, due to the potential for decreased glucose tolerance, and in those with conditions exacerbated by fluid retention, such as cardiac or renal dysfunction.

Advertisements

Overdose and Emergency Response

The official regulatory labeling for Hydroxyprogesterone caproate does not describe a unique, acute clinical syndrome for massive overdose, with the dedicated Overdosage section providing limited explicit information on specific symptoms.

Regulatory authorities focus on the potential for severe adverse reactions that may be exacerbated by exposure to higher dosage levels. Serious systemic risks include thromboembolic events such as pulmonary emboli, deep vein thrombosis, and stroke, as well as neuroocular lesions (retinal thrombosis, optic neuritis). Furthermore, the likelihood of severe allergic-like reactions, including symptoms like coughing, dyspnea (troubled breathing), and constriction of the chest, may be increased with higher doses.

In the event of a suspected overdose or the manifestation of any severe symptoms, immediate medical attention must be sought. Official regulatory guidance requires that the medication be discontinued promptly if signs of a thromboembolic or neuroocular event appear. Management of potential over-exposure is strictly symptomatic and supportive, as no specific antidote is known for Hydroxyprogesterone caproate. Hospital monitoring and observation are required for the management of potentially life-threatening systemic events.

Advertisements

Therapeutic Uses of Proluton Depot

Support for High-Risk Pregnancy Maintenance

This long-acting progestin is used in women with a history of spontaneous preterm delivery to help reduce the risk of this complication recurring in subsequent singleton pregnancies. By providing support that helps ease the overall symptom burden, the medication supports the patient during episodes of heightened discomfort and may assist with maintaining functional stability during periods of heightened physiological stress.

Management of Hormone-Related Gynecological Conditions

Proluton Depot is applicable in non-pregnant individuals to manage specific menstrual disorders that stem from hormonal insufficiency. This is commonly used to help with the complete absence of menstruation (amenorrhea) or helping to regulate cases of abnormal uterine bleeding that are caused by hormonal imbalance rather than underlying organic pathology.

Supportive Management in Hormone-Sensitive Conditions

A distinct use is in specific contexts involving hormone-sensitive conditions, specifically as a systemic palliative treatment for advanced stages (Stage III or IV) of adenocarcinoma of the uterine corpus. This hormonal support may be part of symptomatic management and is applied in addressing the systemic burden of these hormone-sensitive conditions as part of a comprehensive care strategy.

“In high-risk patients, continuous hormonal support helps with maintaining functional stability in conditions characterized by periods of heightened symptoms.”

Quick Fact: Relief for Progestin Deficiency
Primary Goal Provides supportive relief when symptoms interfere with routine activities in situations involving progestin insufficiency.
Core Symptom Relief Supports the stability of the reproductive system, easing the functional strain of systemic imbalance.
Target Conditions Recurrent spontaneous preterm birth, amenorrhea, and specific advanced uterine cancers.

Regulatory References

  1. DailyMed resource from the NIH National Library of Medicine
Advertisements

Eligibility and Restrictions for Use

The official eligibility profile for Proluton Depot is structured by mandatory regulatory prohibitions and specific population restrictions. The medicine is primarily allowed for non-pregnant women receiving treatment for specific gynecological disorders or advanced adenocarcinoma of the uterine corpus.

Absolute contraindications prohibit use in patients with a current or history of thrombosis or thromboembolic disorders, uncontrolled hypertension, active liver disease or tumors, and known or suspected hormone-sensitive cancers (such as breast cancer). Undiagnosed abnormal vaginal bleeding is also a formal prohibition.

Regarding age, use is not indicated for the pediatric population (under 16) and is not recommended for geriatric women. Conditional use requires careful monitoring for conditions sensitive to fluid retention, including renal dysfunction, epilepsy, or asthma, and in women with prediabetes or diabetes.

In pregnant women, the indication for preventing recurrent preterm birth has been revoked by the US FDA and its use suspension is recommended by the EMA, effectively limiting use in this population. Use during breastfeeding is permitted, but regulatory labeling advises caution.

Advertisements

What should I know about interactions with other medicines?

Interactions with other medicines and products

The official regulatory profile for Hydroxyprogesterone caproate (Proluton Depot) establishes interaction patterns based on its specific metabolic and pharmacodynamic characteristics. The primary pharmacokinetic interaction concern is rooted in the drug's metabolism, which is predominantly mediated by the CYP3A4 and CYP3A5 liver enzymes. Co-administration with strong CYP3A inducers (such as Rifampin) is expected to decrease the overall systemic exposure and plasma concentration of hydroxyprogesterone caproate due to accelerated breakdown. Conversely, co-administration with strong CYP3A inhibitors (such as Ketoconazole) may increase the drug's systemic exposure due to reduced clearance.

Official Interaction Restrictions

Interaction Type Regulatory Context
Drug-Drug Contraindications No specific medicinal products are formally listed as contraindicated solely due to interaction risk in the official labeling.
Pharmacodynamic Risk The medicine's effect on coagulation factors creates a documented pharmacodynamic interaction risk with other medicines that affect blood clotting, specifically the potential for additive thromboembolic events.
Population-Specific Note Clearance is dependent on liver function; hepatic impairment may reduce elimination, which is a key interaction consideration.

No timing-based separation rules or specific interactions with food, alcohol, or herbal products are explicitly documented in regulatory prescribing information.

Advertisements

Mechanism of Action

Proluton Depot (hydroxyprogesterone caproate) functions primarily as a synthetic progestin agonist, modulating reproductive physiology by binding to the intracellular progesterone receptor (PR). This binding initiates a complex receptor-mediated signaling cascade by engaging both PR-A and PR-B isoforms, which translocate to the nucleus to regulate target gene expression in tissues such as the uterus.

At the cellular level, this activation modifies signaling sequences within the myometrium. It initiates mechanisms that oppose factors triggering myometrial contraction, increasing the threshold for excitation within the uterine muscle tissue. This localized effect alters the baseline electrical and contractile activity. Furthermore, its caproate formulation provides a specialized delivery mechanism, resulting in sustained concentration profiles that modulate pathway activity over an extended duration, providing prolonged engagement with the progesterone receptors and maintenance of the resulting cellular state.

Advertisements

Dosage and Administration Information

The use of Proluton Depot is guided by standardized, prescriptive protocols. The medicine is a parenteral injection and must be administered exclusively by a trained healthcare provider in a clinical setting.

Administration Method and Dosing

The medication is administered either as an Intramuscular (IM) injection or, with specific formulations, as a Subcutaneous (SC) injection. For IM administration, the procedure requires a slow injection delivered over one minute or longer, typically into the upper outer quadrant of the gluteus maximus. The administration site must be rotated weekly with each subsequent dose.

The standard labeled regimen for reducing the risk of recurrent preterm delivery involves a fixed dose of 250 mg (IM) or 275 mg (SC). This dose is administered precisely once every seven days.

Timing and Course Duration

For pregnancy maintenance, treatment must be initiated within a specific window, generally between 16 weeks and 21 weeks of gestation. The weekly dosing schedule continues consistently until the patient reaches 37 weeks of gestation or delivery. For other approved uses, such as advanced uterine corpus adenocarcinoma, the dose may be significantly higher, often 1,000 mg or more weekly, and the duration is contingent upon the patient's response.

Prior to administration, the solution must be visually inspected by the healthcare provider to confirm it is clear and yellow; product that is cloudy or contains solid particles must not be used. Use is also restricted by age; the medicine is not indicated for patients under 16 years of age or intended for postmenopausal women over 65.

Advertisements

Recent Clinical Evidence

Research Evidence: Overview of Studies for Proluton Depot

Evidence for Use in Preventing Recurrent Preterm Birth

Researchers have focused significant effort on understanding Proluton Depot's use in research settings examining pregnancies for women who have previously experienced a spontaneous preterm birth. This research has primarily involved multiple controlled studies, known as Randomized Controlled Trials (RCTs), as well as large reviews (meta-analyses).

Early studies and some subsequent analyses reported measurements where the rate of recurrent delivery before 37 weeks was measured in the group receiving Proluton Depot compared to the groups receiving an inactive substance (placebo). However, subsequent large-scale research has reported mixed findings regarding the primary outcome examined (delivery before 37 weeks). These differing outcomes across studies mean that the overall pattern is not consistent or fully characterized.

Research on Proluton Depot in Fertility Treatments

Proluton Depot was studied for a different use in the context of fertility treatments, specifically as a component of luteal phase support following procedures like in vitro fertilization (IVF). The research scenarios here involved small comparative studies and trials where researchers examined its use, often in addition to standard vaginal progesterone. The studies monitored clinical pregnancy rates, live birth rates, and pregnancy loss rates.

Long-Term Studies and Follow-up Data

Research explored events tracked beyond the mother's immediate pregnancy. Specifically, studies monitored the health and development of children whose mothers were observed in trials involving Proluton Depot. This includes tracking outcomes such as neurodevelopmental disability over the child's first few years of life, and in some population-based reports, tracking potential associations with health markers over longer periods. Long-term effects are not fully established, and continued research is ongoing in this area.

What is Still Uncertain About the Research Evidence

Across all indications, the evidence quality varies across studies, and the overall certainty of the findings is limited in some areas. Specifically, findings were mixed regarding the core outcome examined (delivery before 37 weeks). Furthermore, data for certain groups are limited, including patients with specific comorbidities or those outside the main trial demographics. Researchers describe that these limitations mean the current research primarily provides context based on group patterns.

Key Studies & References

  1. American College of Obstetricians and Gynecologists (ACOG) Practice Bulletin No. 248: Prediction and Prevention of Spontaneous Preterm Birth
Advertisements

Frequently Asked Questions (FAQ)

Common questions about Proluton Depot (FAQ)


Q: How quickly does Proluton Depot start working after injection?

Proluton Depot is designed to be a long-acting injection. According to regulatory information, the highest level of the active ingredient in the bloodstream is generally measured between 3 to 7 days following a single intramuscular injection. This sustained release helps maintain the hormonal effect over a longer period.


Q: Can Proluton Depot cause mood swings or anxiety?

Official drug labeling lists mental depression as a potential systemic side effect. Additionally, based on some reports from clinical experience, effects such as anxiety have also been noted. A healthcare provider should be informed if a patient experiences unexpected or concerning changes in mood.


Q: Why do some people say Proluton Depot causes injection site pain?

Injection site pain is a well-documented and very common adverse reaction, meaning it occurs in 10% or more of patients during clinical trials. Regulatory documents acknowledge this reaction. The pain is a localized effect linked to the intramuscular administration of the oil-based solution.


Q: Is Proluton Depot the same as other progesterone shots?

No, Proluton Depot is not the same as all other progesterone shots. It contains Hydroxyprogesterone caproate (17-OHPC), a synthetic progestin and a depot preparation designed for a long-acting effect. This specific chemical structure and formulation make it distinct from natural progesterone or other shorter-acting progesterone injections.


Q: Are there any long-term effects of using Proluton Depot during pregnancy?

The long-term effects of the drug on the child are not fully established, and continuous follow-up studies are ongoing as requested by regulatory bodies. While some studies have not found differences in neurodevelopment, the potential for other effects, including possible increased risk of cancer in offspring, has been noted in some reports.


Q: How long after the last shot of Proluton Depot does the medicine leave the body?

Proluton Depot is designed for a sustained-release effect, which means the active ingredient is released slowly from the injection site over time. While the effect is prolonged, patient information generally does not provide a specific timeframe or elimination half-life for when the drug is completely cleared from the body.


Q: Is Proluton Depot considered safe for the developing fetus?

Regulatory reviews, such as those by the US FDA, have concluded that the known risks, including potential effects on the fetus/offspring, outweigh the unproven benefits for its original pregnancy indication. Major regulatory bodies have either revoked the approval or recommended the suspension of this indication.


Q: What's the difference between Proluton Depot and oral progesterone pills?

The primary difference is the route and timing of administration. Proluton Depot is an oil-based solution for injection (parenteral) that provides a sustained, long-acting hormonal effect. Oral progesterone pills are taken by mouth and typically provide a shorter-acting hormonal influence.


Q: Is it normal to feel tired after a Proluton Depot injection?

Systemic symptoms such as feeling tired or having a general feeling of weakness have been noted in regulatory documents based on post-marketing experience and clinical trials. A healthcare professional should be consulted if this symptom is severe or persistent.


Q: Does Proluton Depot interact with common over-the-counter pain relievers?

Official labeling does not specify drug interaction information for most common over-the-counter (OTC) pain relievers. However, regulatory guidance consistently advises patients to inform their healthcare provider about all prescription and non-prescription medicines, including OTC products.


Q: Are there specific vitamins or supplements that interact with Proluton Depot?

Official drug interaction profiles primarily focus on prescription drugs. While the labeling does not list specific vitamins or supplements, patients are advised in regulatory documents to discuss the use of any herbal or vitamin supplements with their healthcare provider.


Q: Is Proluton Depot always given in the same location on the body?

No, the medicine is administered as an intramuscular injection, typically into the upper outer quadrant of the gluteus maximus. According to the official administration instructions, the injection site must be rotated weekly with each subsequent dose.


Q: Does Proluton Depot affect blood sugar levels?

Yes, regulatory documents contain a warning that progestins can potentially decrease glucose tolerance. For patients with existing diabetes or pre-diabetes, close monitoring of blood sugar levels by the healthcare provider is generally necessary throughout the course of treatment.


Q: Has Proluton Depot been approved in all countries for pregnancy support?

No, this medicine is not approved or recommended for pregnancy support in all countries. Major regulatory bodies, including the US FDA and the European Medicines Agency (EMA), have either revoked the approval or recommended the suspension of this indication due to a lack of demonstrated clinical effectiveness.


Q: Can older women use Proluton Depot for hormone replacement therapy?

The medicine is not indicated for use in the pediatric population (under 16) and is also not recommended for women over 65 years of age (the geriatric population). Its primary uses are for certain gynecological disorders or cancers.


Q: Does alcohol consumption affect the effectiveness of Proluton Depot?

While specific interactions with alcohol are not explicitly documented in the official prescribing information, regulatory bodies advise that patients should always discuss their use of alcohol and other substances with their healthcare professional.


Q: Is it common to have mild headaches while on Proluton Depot?

Headache is listed as a systemic adverse reaction in regulatory documents, meaning it has been reported by patients. However, the official labeling may not always specify whether this event is common or uncommon across all patient groups.


Q: Are there specific warnings for people with asthma or migraines using Proluton Depot?

Official warnings state that patients with conditions that may be aggravated by fluid retention, such as asthma or migraine headaches, require careful monitoring. Monitoring may be necessary due to the potential for fluid retention side effects.


Q: What kind of studies have been done on the safety of Proluton Depot?

The safety information for this medicine is based on data collected from Randomized Controlled Trials (RCTs), post-marketing experience involving reported adverse events, and long-term observational follow-up studies conducted on children whose mothers received the treatment.


Q: Do you need to get blood tests while on Proluton Depot?

Regulatory information advises that patients with certain pre-existing health conditions (such as diabetes) or those receiving treatment for non-pregnant indications may need to have their blood work and other laboratory tests checked by their healthcare provider. It may be necessary to get blood tests for monitoring.

Advertisements

How should Proluton Depot be stored and disposed of?

Storage and Disposal of Proluton Depot

The storage and disposal of Proluton Depot (hydroxyprogesterone caproate injection) must adhere strictly to regulatory requirements to ensure product quality and safety.


Storage Requirements

The medicine must be stored at controlled room temperature, specifically between 20 C and 25 C (68 F and 77 F). It is mandatory to protect the vial from light, often by storing it in its original box, and the product must not be refrigerated or frozen. Multi-dose vials must be discarded 28 days after first use. The medication must be kept out of the reach and sight of children.


Disposal Instructions

All used needles and syringes must be placed immediately in an FDA-cleared, puncture-resistant sharps disposal container. Any unused or expired medicine must be disposed of in accordance with local pharmaceutical waste regulations and should not be discarded in household trash or wastewater.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Proluton Depot found in:

A-Z Index: